Medicinal cannabis in oncology

F. K. Engels; F. A. de Jong; R. H. Mathijssen; J. A. Erkens; R. M. Herings; J. Verweij

doi:10.1016/j.ejca.2007.09.010

Medicinal cannabis in oncology

F. K. Engels
, F. A. de Jong
, R. H. Mathijssen
, J. A. Erkens
, R. M. Herings
, J. Verweij

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In The Netherlands, since September 2003, a legal medicinal cannabis product, constituting the whole range of cannabinoids, is available for clinical research, drug development strategies, and on prescription for patients. To date, this policy, initiated by the Dutch Government, has not yet led to the desired outcome; the amount of initiated clinical research is less than expected and only a minority of patients resorts to the legal product. This review aims to discuss the background for the introduction of legal medicinal cannabis in The Netherlands, the past years of Dutch clinical experience in oncology practice, possible reasons underlying the current outcome, and future perspectives.

Original language	English
Pages (from-to)	2638-2644
Number of pages	7
Journal	European Journal of Cancer
Volume	43
Issue number	18
DOIs	https://doi.org/10.1016/j.ejca.2007.09.010
Publication status	Published - 2007
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anorexia/prevention & control Attitude to Health Cannabinoids/*therapeutic use *Cannabis Forecasting Health Policy Humans Legislation, Drug Nausea/prevention & control Neoplasms/*complications Netherlands Pain/prevention & control *Phytotherapy Vomiting/prevention & control

Access to Document

10.1016/j.ejca.2007.09.010

https://www.ncbi.nlm.nih.gov/pubmed/17976975

Cite this

@article{4126f7fb3dda4c84adc42b2a2709c143,

title = "Medicinal cannabis in oncology",

abstract = "In The Netherlands, since September 2003, a legal medicinal cannabis product, constituting the whole range of cannabinoids, is available for clinical research, drug development strategies, and on prescription for patients. To date, this policy, initiated by the Dutch Government, has not yet led to the desired outcome; the amount of initiated clinical research is less than expected and only a minority of patients resorts to the legal product. This review aims to discuss the background for the introduction of legal medicinal cannabis in The Netherlands, the past years of Dutch clinical experience in oncology practice, possible reasons underlying the current outcome, and future perspectives.",

keywords = "Anorexia/prevention \& control Attitude to Health Cannabinoids/*therapeutic use *Cannabis Forecasting Health Policy Humans Legislation, Drug Nausea/prevention \& control Neoplasms/*complications Netherlands Pain/prevention \& control *Phytotherapy Vomiting/prevention \& control",

author = "Engels, \{F. K.\} and \{de Jong\}, \{F. A.\} and Mathijssen, \{R. H.\} and Erkens, \{J. A.\} and Herings, \{R. M.\} and J. Verweij",

note = "Engels, Frederike K de Jong, Floris A Mathijssen, Ron H J Erkens, Joelle A Herings, Ron M Verweij, Jaap eng Review England Eur J Cancer. 2007 Dec;43(18):2638-44. doi: 10.1016/j.ejca.2007.09.010. Epub 2007 Oct 31.",

year = "2007",

doi = "10.1016/j.ejca.2007.09.010",

language = "English",

volume = "43",

pages = "2638--2644",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "18",

}

TY - JOUR

T1 - Medicinal cannabis in oncology

AU - Engels, F. K.

AU - de Jong, F. A.

AU - Mathijssen, R. H.

AU - Erkens, J. A.

AU - Herings, R. M.

AU - Verweij, J.

N1 - Engels, Frederike K de Jong, Floris A Mathijssen, Ron H J Erkens, Joelle A Herings, Ron M Verweij, Jaap eng Review England Eur J Cancer. 2007 Dec;43(18):2638-44. doi: 10.1016/j.ejca.2007.09.010. Epub 2007 Oct 31.

PY - 2007

Y1 - 2007

N2 - In The Netherlands, since September 2003, a legal medicinal cannabis product, constituting the whole range of cannabinoids, is available for clinical research, drug development strategies, and on prescription for patients. To date, this policy, initiated by the Dutch Government, has not yet led to the desired outcome; the amount of initiated clinical research is less than expected and only a minority of patients resorts to the legal product. This review aims to discuss the background for the introduction of legal medicinal cannabis in The Netherlands, the past years of Dutch clinical experience in oncology practice, possible reasons underlying the current outcome, and future perspectives.

AB - In The Netherlands, since September 2003, a legal medicinal cannabis product, constituting the whole range of cannabinoids, is available for clinical research, drug development strategies, and on prescription for patients. To date, this policy, initiated by the Dutch Government, has not yet led to the desired outcome; the amount of initiated clinical research is less than expected and only a minority of patients resorts to the legal product. This review aims to discuss the background for the introduction of legal medicinal cannabis in The Netherlands, the past years of Dutch clinical experience in oncology practice, possible reasons underlying the current outcome, and future perspectives.

KW - Anorexia/prevention & control Attitude to Health Cannabinoids/therapeutic use Cannabis Forecasting Health Policy Humans Legislation, Drug Nausea/prevention & control Neoplasms/complications Netherlands Pain/prevention & control Phytotherapy Vomiting/preve

U2 - 10.1016/j.ejca.2007.09.010

DO - 10.1016/j.ejca.2007.09.010

M3 - Article

SN - 0959-8049

VL - 43

SP - 2638

EP - 2644

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 18

ER -

Medicinal cannabis in oncology

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this